ETHOS HOLDING CORP NPI 1104255215

NPI Details

ETHOS HOLDING CORP is a clinical medical laboratory in Newport, KY. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. ETHOS HOLDING CORP NPI is 1104255215. The provider is registered as an organization entity type.
The provider Is Doing Business As Ethos Laboratory.

The provider's business location address is:

29 E 6TH ST
NEWPORT, KY
ZIP 41071-803
Phone: (513) 889-4423

The provider's authorized official is Brian Kincaid .
The authorized official title is Ceo/owner and has the following contact phone number (513) 889-4423.

The CLIA number assigned to this NPI record is 18D2067771 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count (HCPCS:K1034)
• 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0004)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (HCPCS:G2023)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Analysis of 11 biochemical substances in urine to evaluate likelihood of atypical biochemical function associated with pain (HCPCS:0117U)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Creatinine level to test for kidney function or muscle injury (HCPCS:82570)
• Mass spectrometry (laboratory testing method) (HCPCS:83789)
• Organic acid level (HCPCS:83921)
• Chemical analysis using chromatography technique (HCPCS:82542)
• Organic acids level (HCPCS:83918)
• Homocysteine (amino acid) level (HCPCS:83090)
• Hydroxyindolacetic acid (product of metabolism) level (HCPCS:83497)
• Vitamin b-6 level (HCPCS:84207)
• Urine vanillylmandelic acid (HCPCS:84585)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Hemoglobin a1c level (HCPCS:83036)
• Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 19) common variants (HCPCS:81225)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Vitamin d-3 level (HCPCS:82306)
• Magnesium level (HCPCS:83735)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b (HCPCS:87636)
• Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 9) common variants (HCPCS:81227)
• Detection test by immunoassay technique for influenza virus (HCPCS:87400)
• Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants (HCPCS:81226)

The enumeration date for this NPI number is 11/8/2013 and was last updated on 10/26/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: